Immune Responses to Tumours in the CNS

Neuroinflammation and CNS Disorders

Volumn , Issue , 2014, Pages 363-384

  Gielen, Paul ^a   Van Der Valk, Paul ^b   Wesseling, Pieter ^b,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CNS tumour; Glioma; Immune response; Immunopathology; Immunotherapy; Meningioma

Indexed keywords

EID: 84942789986     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118406557.ch15     Document Type: Chapter

References (51)

1. Anderson, R.C., Anderson, D.E., Elder, J.B., et al., 2007. Lack of B7 expression, not human leukocyte antigen expression, facilitates immune evasion by human malignant gliomas. Neurosurgery 60, 1129-1136; discussion 1136.
2. Aronica, E., Gorter, J.A., Redeker, S., et al., 2005. Distribution, characterization and clinical significance of microglia in glioneuronal tumours from patients with chronic intractable epilepsy. Neuropathol. Appl. Neurobiol. 31, 280-291.
3. Behrem, S., Zarkovic, K., Eskinja,N., Jonjic,N., 2005. Distribution pattern of tenascin-C in glioblastoma: correlation with angiogenesis and tumor cell proliferation. Pathol. Oncol. Res. 11, 229-235.
4. Burnet, N.G., Jefferies, S.J., Benson, R.J., et al., 2005. Years of life lost (YLL) from cancer is an important measure of population burden - and should be considered when allocating research funds. Br. J. Cancer 92, 241-245.
5. Claes, A., Idema, A.J.,Wesseling, P., 2007. Diffuse glioma growth: a guerilla war.Acta Neuropathol. 114, 443-458.
6. Cserr, H.F., Knopf, P.M., 1992. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol. Today 13, 507-512.
7. Daneman, R., 2012. The blood-brain barrier in health and disease. Ann. Neurol. 72, 648-672.
8. De Micco, C., 1989. Immunology of central nervous system tumors. J. Neuroimmunol. 25, 93-108.
9. Dolecek, T.A., Propp, J.M., Stroup, N.E., Kruchko, C., 2012. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro. Oncol. 14 (Suppl. 5), v1-49.
10. Engler, J.R., Robinson, A.E., Smirnov, I., et al., 2012. Increased microglia/ macrophage gene expression in a subset of adult and pediatric astrocytomas. PLoS One 7, e43339.
11. Essand, M., Loskog, A.S., 2013. Genetically engineered T cells for the treatment of cancer. J. Intern. Med. 273, 166-181.
12. Fecci, P.E., Mitchell, D.A., Whitesides, J.F., et al., 2006. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 66, 3294-3302.
13. Gousias, K., Markou, M., Arzoglou, V., et al., 2010. Frequent abnormalities of the immune system in gliomas and correlation with the WHOgrading system of malignancy. J. Neuroimmunol. 226, 136-142.
14. Graeber, M.B., Scheithauer, B.W., Kreutzberg, G.W., 2002. Microglia in brain tumors. Glia 40, 252-259.
15. Grauer, O.M., Wesseling, P., Adema, G.J., 2009. Immunotherapy of diffuse gliomas: biological background, current status and future developments. Brain Pathol. 19, 674-693.
16. Hanahan, D., Weinberg, R.A., 2000. The hallmarks of cancer. Cell 100, 57-70.
17. Hanahan, D., Weinberg, R.A., 2011. Hallmarks of cancer: the next generation. Cell 144, 646-674.
18. Hanisch, U.K., Kettenmann, H., 2007. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 10, 1387-1394.
19. Hart, D.N., Fabre, J.W., 1981. Demonstration and characterization of Ia-positive dendritic cells in the interstitial connective tissues of rat heart and other tissues, but not brain. J. Exp. Med. 154, 347-361.
20. Hasselblatt, M., Gesk, S., Oyen, F., et al., 2011. Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression. Am. J. Surg. Pathol. 35, 933-935.
21. Hussain, S.F., Yang, D., Suki, D., et al., 2006. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro. Oncol. 8, 261-279.
22. Jacobs, J.F., Idema, A.J., Bol, K.F., et al., 2009. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol, 11, 394-402.
23. Jacobs, J.F., Idema, A.J., Bol, K.F., et al., 2010. Prognostic significance and mechanism of Treg infiltration in human brain tumors. J. Neuroimmunol. 225, 195-199.
24. Johnson, T.S., Munn, D.H., Maria, B.L., 2012. Modulation of tumor tolerance in primary central nervous system malignancies. Clin. Dev. Immunol. 2012, 937253.
25. Kohanbash, G., McKaveney, K., Sakaki, M., et al., 2013. GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α. Cancer Res. 73, 6413-6423.
26. Kohanbash, G., Okada, H., 2012. Myeloid-derived suppressor cells (MDSCs) in gliomas and glioma-development. Immunol. Invest. 41, 658-679.
27. Lindau, D., Gielen, P., Kroesen, M., et al., 2013. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 138, 105-115.
28. Liu, G., Ying, H., Zeng, G., et al., 2004. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. CancerRes. 64, 4980-4986.
29. Lohr, J., Ratliff, T., Huppertz, A., et al., 2011. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGFbeta. Clin. Cancer Res. 17, 4296-4308.
30. Louis, D.N., Ohgaki, H.,Wiestler, O.D., Cavenee,W.K., 2007. WHO Classification of Tumours of the Central Nervous System. IARC Press, Lyon, France.
31. Maes, W., Verschuere, T., Van Hoylandt, A., et al., 2013. Depletion of regulatory T cells in a mouse experimental glioma model through anti-CD25 treatment results in the infiltration of non-immunosuppressive myeloid cells in the brain. Clin. Dev. Immunol. 2013, 952469.
32. Mcmahon, E.J.,Bailey, S.L., Miller, S.D., 2006.CNSdendritic cells: critical participants in CNS inflammation? Neurochem Int, 49, 195-203.
33. Mitchell, D.A., Fecci, P.E., Sampson, J.H., 2008. Immunotherapy of malignant brain tumors. Immunol. Rev. 222, 70-100.
34. Morgan, R.A., Johnson, L.A.,Davis, J.L., et al., 2012. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum. Gene Ther. 23, 1043-1053.
35. Northcott, P.A., Jones, D.T., Kool, M., et al., 2012. Medulloblastomics: the end of the beginning. Nat. Rev. Cancer 12, 818-834.
36. Pfister, S.M., Korshunov, A., Kool, M., et al., 2010. Molecular diagnostics of CNS embryonal tumors. Acta Neuropathol. 120, 553-566.
37. Prins, R.M., Soto, H., Konkankit, V., et al., 2011. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin. Cancer Res. 17, 1603-1615.
38. Raychaudhuri, B., Rayman, P., Ireland, J., et al., 2011. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro. Oncol. 13, 591-599.
39. Riemenschneider, M.J., Jeuken, J.W.,Wesseling, P., Reifenberger, G., 2010. Molecular diagnostics of gliomas: state of the art. Acta Neuropathol. 120, 567-584.
40. Roggendorf, W., Strupp, S., Paulus, W., 1996. Distribution and characterization of microglia/macrophages in human brain tumors. Acta Neuropathol. 92, 288-293.
41. Sampson, J.H., Heimberger, A.B., Archer,G.E., et al., 2010. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28, 4722-4729.
42. Scheurer, M.E., Bondy, M.L., Aldape, K.D., et al., 2008. Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol. 116, 79-86.
43. Strik, H.M., Stoll, M., Meyermann, R., 2004. Immune cell infiltration of intrinsic and metastatic intracranial tumours. Anticancer Res. 24, 37-42.
44. Sturm,D.,Witt, H., Hovestadt,V., et al., 2012. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22, 425-437.
45. Verhaak, R.G., Hoadley, K.A., Purdom, E., et al., 2010. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110.
46. Xu, X., Stockhammer, F., Schmitt, M., 2012. Cellular-based immunotherapies for patients with glioblastoma multiforme. Clin. Dev. Immunol. 2012, 764213.
47. Yang, I., Han, S.J., Kaur, G., et al., 2010a. The role of microglia in central nervous system immunity and glioma immunology. J. Clin. Neurosci. 17, 6-10.
48. Yang, I., Han, S.J., Sughrue, M.E., et al., 2011. Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology. J. Neurosurg. 115, 505-511.
49. Yang, I., Tihan, T., Han, S.J., et al., 2010b. CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. J. Clin. Neurosci. 17, 1381-1385.
50. Zhang, J., Sarkar, S., Cua, R., et al., 2012. A dialog between glioma and microglia that promotes tumor invasiveness through the CCL2/CCR2/interleukin-6 axis. Carcinogenesis 33, 312-319.
51. Zhang, J.G., Eguchi, J., Kruse, C.A., et al., 2007. Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin. Cancer Res. 13, 566-575.